Name: Latest research reports of Biocon Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 5
Author: Motilal Oswal

Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Strong Performer, Getting Expensive

396.8500 1.70 (0.43%)

NSE Nov 21, 2025 15:31 PM

New 52W High in past week

Volume: 3.3M

Biocon Ltd.

12 Nov 2025

396.85

0.43%

Operationally in-line 2Q; healthy growth in core business

Buy: Biocon Ltd.

Target

Motilal Oswal

Biocon (BIOS) delivered in-line revenue/EBITDA for 2QFY26. PAT for the quarter was better than expected, driven by lower minority interest for the quarter.

Biocon Ltd. has an average target of 390.50 from 4 brokers.